Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders

Rhea-AI Summary

Sharp Therapeutics Corp. (TSXV: SHRX, OTC: SHRXF) reported the results of its annual general meeting of shareholders held on July 21, 2026. All director nominees listed in the June 17, 2026 amended and restated management information circular were elected and the board size was set at six directors.

According to Sharp, director election support ranged from 99.97% to 100%, with up to 17,815,481 shares voted for each nominee and, at most, 5,000 shares withheld. Shareholders also re-appointed MNP LLP as auditors, with 17,815,481 shares (100%) voted in favour, and authorized the board to set auditor remuneration. In addition, shareholders provided 100% approval (17,815,481 shares for) to re-approve the Company’s rolling 10% stock option plan. Sharp reiterates it is a preclinical-stage biotechnology company developing small-molecule therapies for genetic diseases using a proprietary discovery platform.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 21, 2026 (the "Meeting").

All nominees set forth in the Company's amended and restated management information circular dated June 17, 2026 (the "Circular") were elected as directors of the Company at the Meeting and the number of directors of the Company was set at six (6).

Detailed results of the shareholder votes for the elected directors are set out below:

Nominee	Number of Shares		Percentage of Votes
	For	Withheld	For	Withheld
Scott Sneddon	17,815,481	0	100%	0%
William R. Newlin	17,810,481	5,000	99.97%	0.03%
John L. Brooks III	17,810,481	5,000	99.97%	0.03%
Dietrich Stephan	17,815,481	0	100%	0%
John Hathaway	17,815,481	0	100%	0%
Lorne Sugarman	17,810,481	5,000	99.97%	0.03%

 

The Circular also sought approval to re-appoint MNP LLP as auditors of the Company and to authorize the board of directors of the Company to fix the auditors' remuneration. The results of the shareholder votes for the re-appointment of the auditors are set out below:

Motion	Number of Shares For	Percentage of Votes For
Appointment of Auditors	17,815,481	100%

 

Lastly, the Circular sought re-approval of the Company's rolling 10% stock option plan (the "Plan"). The results of the shareholder votes for the re-approval of the Plan is set out below:

Motion	Number of Shares For	Percentage of Votes For
Approval of Plan	17,815,481	100%

 

About Sharp Therapeutics Corp.

First-Choice Therapies for Genetic Diseases

Sharp Therapeutics is a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's small molecule discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.

For additional information on Sharp, please visit: www.sharptx.com.

Sharp Therapeutics Corp.

Scott Sneddon, PhD, JD CEO/CSO
Email: scott@sharptx.com
Phone: (412) 206-5303

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305977

FAQ

What did Sharp Therapeutics (SHRXF) announce from its July 21, 2026 annual meeting?

Sharp Therapeutics reported that all director nominees were elected, auditors re-appointed, and its 10% stock option plan re-approved. According to Sharp, these items each received 17,815,481 votes in favour, representing up to 100% shareholder support on the disclosed motions.

Were all Sharp Therapeutics (SHRXF) director nominees elected at the 2026 shareholder meeting?

Yes. All director nominees in the June 17, 2026 circular were elected at the July 21, 2026 meeting. According to Sharp, each nominee received between 17,810,481 and 17,815,481 votes for, corresponding to support levels from 99.97% to 100% of votes cast.

Did Sharp Therapeutics (SHRXF) shareholders approve the 10% stock option plan in 2026?

Yes. Shareholders re-approved Sharp Therapeutics’ rolling 10% stock option plan at the July 21, 2026 meeting. According to Sharp, the plan received 17,815,481 votes for, representing 100% of votes cast on that specific motion by shareholders present or represented.

Who was appointed auditor of Sharp Therapeutics (SHRXF) at the 2026 annual meeting?

MNP LLP was re-appointed as auditor of Sharp Therapeutics at the 2026 annual meeting. According to Sharp, the appointment of auditors received 17,815,481 votes for, equaling 100% of votes cast, and the board was authorized to fix auditor remuneration.

How many directors will Sharp Therapeutics (SHRXF) have after the July 2026 shareholder vote?

Sharp Therapeutics will have six directors following the July 21, 2026 shareholder meeting. According to Sharp, shareholders set the number of directors at six and elected Scott Sneddon, William R. Newlin, John L. Brooks III, Dietrich Stephan, John Hathaway, and Lorne Sugarman.

What type of company is Sharp Therapeutics (SHRXF) and what does it develop?

Sharp Therapeutics is a preclinical-stage biotechnology company developing small-molecule therapies for genetic diseases. According to Sharp, its discovery platform uses high-throughput screening and computationally optimized libraries targeting cellular trafficking defects and allosteric activation to restore activity in mutated proteins with pill-based medicines.